Paragonix Founder Assumes CEO Role

Paragonix Technologies Inc. has a new leader.

Lisa Anderson, Ph.D., has been elevated to the role of CEO.

“The depth and breadth of Dr. Anderson’s unique experience at Paragonix both from a clinical and well as multinational commercial development perspective underpins her natural progression into the role of CEO.” Board Chairman John Cammett said. “There is no better person to take over the helm of Paragonix than Lisa. The company has passed the proof of concept phase of commercialization and under Lisa’s leadership, the company will be establishing a new era of broad market adoption and expansion of technologies underpinning the product portfolio. Her leadership in the field of organ preservation and deep connection to the transplant community makes her the perfect leader for this new chapter in the company’s growth.”
 
Dr. Anderson succeeds William Edelman, who has served as chairman and CEO since 2012 and recently announced his retirement. Cammett, a member of the board for more than three years, is assuming the role of board chairman.
 
Dr. Anderson brings a wealth of experience to this role, having founded Paragonix and served as the company’s chief operating officer for the past 10 years. Anderson has played a critical role in the company’s continued growth, including commercially scaling the business across the United States and Europe, overseeing the launch of critically-acclaimed products, Paragonix SherpaPak Cardiac Transport System and the LUNGguard Donor Lung Preservation System, and the recent rollout of a first-of-its-kind digital platform for transplant team coordination and clinical logistics.
 
“I am thrilled to lead a highly distinguished team that is on track to bring Paragonix to the next level by expanding our product profile and digitally integrating our full suite to empower both donation and transplant professionals. Our goal is to provide every transplant patient the advantage of advanced organ preservation through collaboration with all the varied stakeholders in the transplant community,” Anderson said. This next era for Paragonix is built upon the foundation Edelman cultivated: “Under Bill’s leadership, Paragonix defined the pathway to a new method of care, achieved multiple FDA clearances and CE marks, and launched two groundbreaking commercial products. We thank him for eleven years of dedicated service.”
 
As part of his retirement remarks, Edelman underscored his pride in the milestones Paragonix has reached throughout his tenure. “With over 750 heart transplants performed utilizing the Paragonix SherpaPak Cardiac Transport System, our products are on a clear path to becoming standard of care,” he said. “What’s more, I look forward to seeing Paragonix continue to evolve and strengthen under Dr. Anderson’s leadership and unwavering commitment to the transplant community.”